The original idea behind the development of transdermal delivery systems for nitrates was to avoid first-pass hepatic metabolism and to achieve constantly high plasma concentrations. The most widely used method is transdermal nitroglycerin patches. Nitroglycerin and ISDN ointments are also available. The increasing knowledge in the field has led to use of these delivery systems over less than 24 h continuously and to the development of new devices which do not provide a constant plasma level over long periods.
KeywordsAngina Pectoris Isosorbide Dinitrate Chronic Congestive Heart Failure Silent Ischemia Anginal Frequency
Unable to display preview. Download preview PDF.
- 2.Rezakovic DE (1985) The use of nitroglycerin patches over 6 months to treat patients with stable angina pectoris. Herz Kreislauf (Suppl 2): 19–21Google Scholar
- 3.Imhof PR, Müller P, Georgopoulos AJ, Garnier B (1985) Nitroderm TTS versus oral isosorbide dinitrate. A double blind trial in patients with angina pectoris. Acta Ther 11: 155Google Scholar
- 12.Bennett ED, Davis AL (1989) A hemodynamic and pharmacokinetic study to assess a new transdermal nitroglycerin preparation in normal subjects. Eur J Clin Pharmacol (in press)Google Scholar
- 13.Schaer DH, Buff LA, Katz RJ (1987) Sustained nitropatch antianginal efficacy utilizing an overnight nitrate-free interval (Abstract). Circulation 76[Suppl IV]: IV–127Google Scholar
- 15.Reiniger G, Rudolph W (1987) Discontinuous nitroglycerin release from transdermal patches: a pharmacokinetic basis for prevention of tolerance (Abstract). Circulation 76[Suppl IV]: IV–127Google Scholar